Soluble complement receptor type 1 prevents human complement-mediated damage of the rabbit isolated heart.
The purpose of this study was to determine if recombinant human soluble CR1 (sCR1) could prevent tissue damage associated with the activation of human complement. Directly mediated human complement-dependent myocardial injury was induced in the rabbit isolated heart perfused with a Krebs-Henseleit buffer containing 6% human plasma. There were three study groups: 1) 6% heat-inactivated human plasma (control); 2) 6% normal human plasma (NHP); or 3) 6% normal human plasma + 20 nM sCR1 (NHP + sCR1). Recorded functional parameters of the control group remained stable throughout the duration of the 70-min protocol. Complement activation in hearts perfused with 6% NHP increased the diastolic pressure; decreased developed pressure; and increased coronary perfusion pressure. These alterations were accompanied by a decrease in the maximum positive and negative dP/dt. Complement activation also increased cardiac muscle lymphatic fluid flow rate. The changes were greatest between 20 and 40 min, but persisted for the duration of the protocol. sCR1 (20 nM) in the perfusate containing 6% NHP prevented the complement-mediated alterations in the systolic, developed, and coronary perfusion pressures. sCR1 prevented the decrement in the positive and negative dP/dt, and the increase in the lymphatic fluid flow rate. Values for each of these parameters in hearts perfused with 6% NHP + sCR1 were not altered from those of controls at any time point in the protocol. Ultrastructural changes were present in tissues perfused with 6% NHP along with immunohistochemical evidence for presence of the terminal C5b-9 complex. sCR1 prevented the ultrastructural changes and the formation of the terminal complex. sCR1 offers significant protection against the cytolytic effects resulting from activation of the human complement system.
Homeister
J W
JW
University of Michigan Medical School, Department of Pharmacology, Ann Arbor 48109-0626.
Satoh
P S
PS
Kilgore
K S
KS
Lucchesi
B R
BR
D000818:Animals; D001794:Blood Pressure; D003167:Complement Activation; D015938:Complement Membrane Attack Complex / Q000032:analysis; D006801:Humans; D007150:Immunohistochemistry; D066298:In Vitro Techniques; D008297:Male; D008854:Microscopy, Electron; D009200:Myocardial Contraction; D009206:Myocardium / Q000276:immunology / Q000648:ultrastructure*; D010477:Perfusion; D011817:Rabbits; D017463:Receptors, Complement 3b / Q000502:physiology*; D011994:Recombinant Proteins / Q000494:pharmacology
D015938:Complement Membrane Attack Complex; D017463:Receptors, Complement 3b; D011994:Recombinant Proteins